A Phase 3 interventional study of 5-Fluorouracil and Carboplatin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 546 sites in 42 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.
Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 23 in phase 3, and was the 11th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States, Puerto Rico
Ages 18+
By country, each count listing its studies:
pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pertuzumab is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 63 · Phase 3 23 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,804 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 104 interventional studies. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 104 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 170 interventional ones that give a count, is one of 17 that started in 2011, is one of 61 in phase 3, and was the 82nd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
10 of the studies testing pertuzumab in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07187752Shandong Cancer Hospital and InstituteIdentification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes | 2026-12-31 |
| NCT04733118MedSIRChemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies testing pertuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\^2 + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
Drug: 5-Fluorouracil · Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab
Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram \[mg/kg\] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m\^2) + epirubicin 90-120 mg/m\^2 or doxorubicin 50 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\^2 for 3 cycles, 75 mg/m\^2 in first cycle and 100 mg/m\^2 in subsequent cycles, or 75 mg/m\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\^2 or epirubicin 90-120 mg/m\^2 + cyclophosphamide 500-600 mg/m\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\^2 + carboplatin AUC 6 (up to 900 milligrams \[mg\]).
Drug: 5-Fluorouracil · Drug: Carboplatin · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Placebo · Drug: Trastuzumab
5-Fluorouracil will be administered as per the schedule specified in the respective arm.
Carboplatin will be administered as per the schedule specified in the respective arm.
Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Docetaxel will be administered as per the schedule specified in the respective arm.
Doxorubicin will be administered as per the schedule specified in the respective arm.
Epirubicin will be administered as per the schedule specified in the respective arm.
Paclitaxel will be administered as per the schedule specified in the respective arm.
Pertuzumab will be administered as per the schedule specified in the respective arm.
Also known as: Perjeta®
Placebo will be administered as per the schedule specified in the respective arm.
Trastuzumab will be administered as per the schedule specified in the respective arm.
Also known as: Herceptin®
Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.
Time frame: Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at 3 years is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
The Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (excluding SPNBC) at 6, 8, and 10 years are reported. IDFS event was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, or contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
Time frame: 6, 8, and 10 years
Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
Time frame: Randomization to the first occurrence of IDFS event (including SPNBC) (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at 3 years is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (including SPNBC) at 6, 8, and 10 years are reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, or SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
Time frame: 6, 8, and 10 years
Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
Time frame: Randomization to the first occurrence of DFS event (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were DFS event-free at 3 years is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimates of the percentage of participants who were DFS event-free at 6, 8, and 10 years are reported. DFS was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, SPNBC, or contralateral or ipsilateral DCIS. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
Time frame: 6, 8, and 10 years
Percentage of Participants Who Died, First Interim Overall Survival Analysis
Percentage of participants who died due to any cause is reported.
Time frame: Randomization until death due to any cause (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Percentage of Participants Who Died, Final Overall Survival Analysis
Percentage of participants who died due to any cause is reported.
Time frame: Randomization until death due to any cause (median [range] follow-up: 11.3 [0-12.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years
The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 6, 8, and 10 Years
The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 6, 8, and 10 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.
Time frame: 6, 8, and 10 years
Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence.
Time frame: Randomization until local, regional or distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were RFI event-free at 3 years is reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimates of the percentage of participants who were RFI event-free at 6, 8, and 10 years are reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
Time frame: 6, 8, and 10 years
Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence.
Time frame: Randomization until distant breast cancer recurrence (until data cut-off date 19 December 2016; median [range] follow-up: 3.8 [0-4.9] years)
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at 3 years is reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
Time frame: 3 years
Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 6, 8, and 10 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings
Kaplan-Meier estimates of the percentage of participants who were DRFI event-free at 6, 8, and 10 years are reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
Time frame: 6, 8, and 10 years
Percentage of Participants With Primary Cardiac Event, Primary Analysis
Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Percentage of Participants With Primary Cardiac Event, Final Analysis
Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Percentage of Participants With Secondary Cardiac Event, Primary Analysis
Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).
Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Percentage of Participants With Secondary Cardiac Event, Final Analysis
Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).
Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Change From Baseline in LVEF to Worst Post-Baseline Value, Primary Analysis
LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
Time frame: Baseline until data cut-off date 19 December 2016 (median [range] follow-up: 3.8 [0.1-4.9] years)
Change From Baseline in LVEF to Worst Post-Baseline Value, Final Analysis
LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
Time frame: Baseline until the end of follow-up (median [range] follow-up: 11.3 [0.1-12.9] years)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Scale Score
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.
Time frame: Baseline, Weeks 13, 25; end of treatment (EOT, 28 days after the last dose, up to Week 56); Follow-up (FU) Months 18, 24, 36
Change From Baseline in EORTC QLQ-C30 Functioning Subscale Scores
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Change From Baseline in EORTC QLQ-C30 Disease/Treatment-Related Symptoms Subscale Scores
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Change From Baseline in EORTC QLQ-C30 Financial Difficulties Subscale Scores
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Change From Baseline in European Organisation for Research and Treatment of Cancer - Breast Cancer Module Quality of Life (EORTC QLQ-BR23) Functional Scale Score
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Percentage of Participants With Response for European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Domain
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Self-Care Domain
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Usual Activities Domain
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Pain/Discomfort Domain
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Percentage of Participants With Response for EQ-5D-3L Questionnaire: Anxiety/Depression Domain
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.
Time frame: Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36
Trough Serum Concentration (Cmin) of Pertuzumab
Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)
Cmin of Trastuzumab
Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)
Peak Serum Concentration (Cmax) of Pertuzumab
Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)
Cmax of Trastuzumab
Time frame: Cycles 1, 10 and 15 (Cycle length=21 days)
Overall, 4804 patients were randomized in the study, 2400 in the Pertuzumab arm and 2404 in the Placebo arm.
| Milestone | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Started | 2400 | 2404 |
| Received at least 1 dose of pertuzumab | 2340 | 24 |
| Received any study treatment except for pertuzumab | 38 | 2367 |
| Entered follow-up | 2369 | 2381 |
| Completed | 1361 | 1316 |
| Not completed | 1039 | 1088 |
| Withdrew: Withdrawal by subject | 475 | 466 |
| Withdrew: Recurrence of disease | 181 | 269 |
| Withdrew: Lost to follow-up | 181 | 176 |
| Withdrew: Death | 41 | 46 |
| Withdrew: Adverse event | 39 | 42 |
| Withdrew: Physician decision | 43 | 32 |
| Withdrew: Contralateral breast cancer | 42 | 28 |
| Withdrew: Reason not specified | 37 | 29 |
The Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (excluding SPNBC) at 6, 8, and 10 years are reported. IDFS event was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, or contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 90.56 (89.35 to 91.77) | 87.76 (86.40 to 89.13) |
| 8 Years | 88.43 (87.10 to 89.76) | 85.76 (84.32 to 87.21) |
| 10 Years | 87.17 (85.77 to 88.57) | 83.82 (82.29 to 85.36) |
Percentage of participants with IDFS events (including SPNBC) is reported. IDFS-SPNBC event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With IDFS Event (Including SPNBC), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 7.9 | 9.6 |
Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (including SPNBC) at 3 years is reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site).
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Including SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 93.50 (92.49 to 94.51) | 92.51 (91.43 to 93.58) |
Kaplan-Meier estimates of the percentage of participants who were IDFS event-free (including SPNBC) at 6, 8, and 10 years are reported. IDFS-SPNBC was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, or SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 89.31 (88.03 to 90.59) | 86.42 (85.00 to 87.44) |
| 8 Years | 87.08 (85.69 to 88.48) | 83.82 (82.29 to 85.34) |
| 10 Years | 85.23 (83.74 to 86.71) | 81.31 (79.69 to 82.93) |
Percentage of participants with DFS event is reported. DFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Disease-Free Survival (DFS) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 8.0 | 9.8 |
Kaplan-Meier estimate of the percentage of participants who were DFS event-free at 3 years is reported. DFS was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer; SPNBC or contralateral or ipsilateral DCIS.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were DFS Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 93.42 (92.40 to 94.43) | 92.29 (91.21 to 93.38) |
Kaplan-Meier estimates of the percentage of participants who were DFS event-free at 6, 8, and 10 years are reported. DFS was defined as the first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, SPNBC, or contralateral or ipsilateral DCIS. Participants who had not had an event at the time of data analysis were censored at the date last known to be alive and event-free.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 88.99 (87.69 to 90.29) | 86.03 (84.59 to 87.47) |
| 8 Years | 86.92 (85.52 to 88.32) | 83.19 (81.64 to 88.74) |
| 10 Years | 85.01 (83.52 to 86.50) | 80.54 (78.89 to 82.19) |
Percentage of participants who died due to any cause is reported.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants Who Died, First Interim Overall Survival Analysis | 3.3 | 3.7 |
Percentage of participants who died due to any cause is reported.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants Who Died, Final Overall Survival Analysis | 8.54 | 10.27 |
The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 3 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were Alive at 3 Years | 97.65 (97.03 to 98.27) | 97.67 (97.06 to 98.29) |
The Kaplan-Meier approach was used to estimate the percentage of participants who were alive at 6, 8, and 10 years. Participants who were alive (including lost to follow-up) at the time of the analysis were censored at the date when they were last known to be alive.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 94.78 (93.85 to 95.71) | 93.93 (92.93 to 94.92) |
| 8 Years | 92.74 (91.66 to 93.82) | 91.96 (90.83 to 93.09) |
| 10 Years | 91.55 (90.38 to 92.71) | 89.79 (88.53 to 91.06) |
Percentage of participants with RFI event is reported. RFI event was defined as local, regional or distant breast cancer recurrence.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Recurrence-Free Interval (RFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 5.8 | 7.2 |
Kaplan-Meier estimate of the percentage of participants who were RFI event-free at 3 years is reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were RFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 95.18 (94.30 to 96.06) | 94.27 (93.32 to 95.21) |
Kaplan-Meier estimates of the percentage of participants who were RFI event-free at 6, 8, and 10 years are reported. RFI event was defined as local, regional or distant breast cancer recurrence. Participants who had not had a recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 92.49 (91.40 to 93.59) | 89.91 (88.66 to 91.16) |
| 8 Years | 92.11 (90.99 to 93.23) | 88.88 (87.59 to 90.18) |
| 10 Years | 91.87 (90.74 to 93.00) | 88.10 (86.76 to 89.44) |
Percentage of participants with DRFI event is reported. DRFI event was defined as distant breast cancer recurrence.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Distant Recurrence-Free Interval (DRFI) Event, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 5.0 | 6.0 |
Kaplan-Meier estimate of the percentage of participants who were DRFI event-free at 3 years is reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were DRFI Event-Free at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 95.70 (94.86 to 96.53) | 95.13 (94.25 to 96.00) |
Kaplan-Meier estimates of the percentage of participants who were DRFI event-free at 6, 8, and 10 years are reported. DRFI event was defined as distant breast cancer recurrence. Participants who had not had a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at their date of death.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| 6 Years | 93.37 (92.34 to 94.40) | 91.57 (90.42 to 92.72) |
| 8 Years | 92.94 (91.88 to 94.01) | 90.69 (89.49 to 91.89) |
| 10 Years | 92.85 (91.78 to 93.92) | 90.01 (88.77 to 91.25) |
Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Primary Cardiac Event (Composite) | 0.7 | 0.3 |
| Heart Failure and LVEF Decline | 0.6 | 0.2 |
| Cardiac Death (Definite or Probable) | 0.1 | 0.1 |
Primary cardiac event was defined as either: Heart Failure (New York Heart Association \[NYHA\] Class III or IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction (EF) points from baseline and to below 50 percent (%); or cardiac death. Cardiac death was defined as either definite cardiac death: due to heart failure, myocardial infarction, or documented primary arrhythmia; or probable cardiac death: sudden unexpected death within 24 hours of a definite or probable cardiac event (e.g., syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Primary Cardiac Event (Composite) | 0.9 | 0.5 |
| Heart Failure and LVEF Decline | 0.8 | 0.3 |
| Cardiac Death (Definite or Probable) | 0.1 | 0.2 |
Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Secondary Cardiac Event, Primary Analysis | 2.7 | 2.8 |
Secondary cardiac event was defined as asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF (defined as an absolute decrease of at least 10 EF points from baseline and to below 50%), confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the Cardiac Advisory Board (CAB).
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Secondary Cardiac Event, Final Analysis | 2.9 | 3.0 |
LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
| percentage of blood pumped out | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline | 65.2 ± 5.9 | 65.3 ± 6.1 |
| Change to Worst Value | -7.5 ± 6.6 | -7.6 ± 6.7 |
LVEF is the fraction of blood (in percent) pumped out of the heart's left ventricular chamber with each heart beat, and is a measure of cardiac output for the heart. Baseline LVEF value and the maximum absolute decrease (worst value) in LVEF measurement from baseline were reported. LVEF was measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan.
| percentage of blood pumped out | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline | 65.2 ± 5.9 | 65.3 ± 6.1 |
| Change to Worst Value | -8.6 ± 6.8 | -8.6 ± 7.0 |
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better GHS/QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline | 72.9 ± 19.7 | 72.5 ± 19.7 |
| Change at Week 13 | -11.2 ± 22.8 | -10.2 ± 22.6 |
| Change at Week 25 | -4.4 ± 21.6 | -2.9 ± 21.0 |
| Change at EOT | -3.1 ± 21.9 | -1.1 ± 21.8 |
| Change at FU Month 18 | 1.9 ± 21.5 | 1.3 ± 22.2 |
| Change at FU Month 24 | 2.2 ± 22.1 | 2.4 ± 22.1 |
| Change at FU Month 36 | 2.8 ± 21.4 | 1.8 ± 22.5 |
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 functioning scores were linearly transformed on a scale of 0 to 100, with a high score indicating better functioning/support. Negative change from Baseline values indicated deterioration in functioning and positive values indicated improvement.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: Physical | 89.6 ± 12.9 | 89.1 ± 13.4 |
| Change at Week 13: Physical | -10.7 ± 17.2 | -10.6 ± 17.7 |
| Change at Week 25: Physical | -4.6 ± 14.5 | -4.3 ± 14.5 |
| Change at EOT: Physical | -4.1 ± 14.7 | -3.2 ± 14.9 |
| Change at FU Month 18: Physical | -0.9 ± 13.5 | -0.9 ± 14.5 |
| Change at FU Month 24: Physical | -0.4 ± 13.8 | -0.3 ± 14.5 |
| Change at FU Month 36: Physical | -0.3 ± 14.1 | -0.1 ± 13.9 |
| Baseline: Role | 79.8 ± 24.7 | 79.4 ± 25.2 |
| Change at Week 13: Role | -8.0 ± 28.6 | -8.5 ± 29.5 |
| Change at Week 25: Role | -0.7 ± 26.4 | 0.4 ± 27.8 |
| Change at EOT: Role | 0.4 ± 27.8 | 2.3 ± 28.1 |
| Change at FU Month 18: Role | 6.1 ± 26.5 | 5.7 ± 28.9 |
| Change at FU Month 24: Role | 7.3 ± 26.8 | 6.9 ± 28.2 |
| Change at FU Month 36: Role | 7.9 ± 26.4 | 7.6 ± 27.9 |
| Baseline: Social | 81.9 ± 22.9 | 80.6 ± 24.1 |
| Change at Week 13: Social | -8.7 ± 25.8 | -7.8 ± 27.1 |
| Change at Week 25: Social | -2.2 ± 24.5 | -0.7 ± 26.3 |
| Change at EOT: Social | 0.0 ± 25.2 | 1.2 ± 26.3 |
| Change at FU Month 18: Social | 5.0 ± 23.8 | 4.8 ± 26.7 |
| Change at FU Month 24: Social | 5.5 ± 24.8 | 6.5 ± 26.6 |
| Change at FU Month 36: Social | 6.6 ± 24.9 | 7.1 ± 27.3 |
| Baseline: Cognitive | 88.8 ± 16.6 | 87.9 ± 17.9 |
| Change at Week 13: Cognitive | -9.1 ± 20.5 | -9.0 ± 21.4 |
| Change at Week 25: Cognitive | -7.6 ± 20.4 | -7.0 ± 20.8 |
| Change at EOT: Cognitive | -7.7 ± 20.6 | -7.2 ± 21.4 |
| Change at FU Month 18: Cognitive | -6.1 ± 19.6 | -5.8 ± 21.2 |
| Change at FU Month 24: Cognitive | -6.2 ± 20.5 | -5.5 ± 21.7 |
| Change at FU Month 36: Cognitive | -5.4 ± 20.6 | -4.9 ± 21.8 |
| Baseline: Emotional | 72.8 ± 22.4 | 71.3 ± 22.7 |
| Change at Week 13: Emotional | 3.3 ± 22.2 | 2.9 ± 22.5 |
| Change at Week 25: Emotional | 5.1 ± 22.7 | 5.9 ± 22.2 |
| Change at EOT: Emotional | 5.6 ± 23.2 | 6.2 ± 23.4 |
| Change at FU Month 18: Emotional | 7.7 ± 23.4 | 7.6 ± 23.4 |
| Change at FU Month 24: Emotional | 7.8 ± 23.3 | 8.5 ± 24.2 |
| Change at FU Month 36: Emotional | 7.8 ± 23.8 | 8.4 ± 24.4 |
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting \[N/V\], constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 disease/treatment-related symptom scores were linearly transformed on a scale of 0 to 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicated improvement in symptoms and positive values indicated worsening of symptoms.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: Diarrhea | 5.2 ± 14.4 | 5.1 ± 13.5 |
| Change at Week 13: Diarrhea | 22.3 ± 29.8 | 9.2 ± 23.9 |
| Change at Week 25: Diarrhea | 13.2 ± 26.5 | 3.3 ± 19.8 |
| Change at EOT: Diarrhea | 12.2 ± 26.9 | 2.9 ± 20.0 |
| Change at FU Month 18: Diarrhea | -0.5 ± 17.7 | 0.2 ± 17.5 |
| Change at FU Month 24: Diarrhea | -0.8 ± 17.4 | 0.2 ± 18.3 |
| Change at FU Month 36: Diarrhea | -0.8 ± 16.5 | 0.3 ± 16.9 |
| Baseline: Fatigue | 22.4 ± 19.7 | 23.2 ± 20.5 |
| Change at Week 13: Fatigue | 16.1 ± 24.3 | 16.2 ± 24.4 |
| Change at Week 25: Fatigue | 7.8 ± 22.5 | 6.6 ± 22.3 |
| Change at EOT: Fatigue | 7.1 ± 23.0 | 5.2 ± 23.0 |
| Change at FU Month 18: Fatigue | 1.1 ± 21.7 | 1.2 ± 22.5 |
| Change at FU Month 24: Fatigue | 0.4 ± 22.0 | 0.4 ± 22.6 |
| Change at FU Month 36: Fatigue | -0.2 ± 21.8 | 0.6 ± 22.8 |
| Baseline: Dyspnea | 6.8 ± 15.5 | 8.0 ± 17.1 |
| Change at Week 13: Dyspnea | 12.3 ± 23.8 | 14.6 ± 26.4 |
| Change at Week 25: Dyspnea | 6.3 ± 19.9 | 6.4 ± 22.1 |
| Change at EOT: Dyspnea | 6.6 ± 20.5 | 6.5 ± 22.5 |
| Change at FU Month 18: Dyspnea | 5.9 ± 21.0 | 5.0 ± 21.5 |
| Change at FU Month 24: Dyspnea | 5.1 ± 20.5 | 5.3 ± 22.4 |
| Change at FU Month 36: Dyspnea | 5.1 ± 20.5 | 5.3 ± 22.3 |
| Baseline: Appetite Loss | 8.5 ± 18.2 | 9.1 ± 18.7 |
| Change at Week 13: Appetite Loss | 13.6 ± 29.2 | 7.7 ± 27.9 |
| Change at Week 25: Appetite Loss | 5.2 ± 25.1 | 0.3 ± 22.4 |
| Change at EOT: Appetite Loss | 3.0 ± 24.5 | -0.9 ± 22.6 |
| Change at FU Month 18: Appetite Loss | -3.0 ± 20.1 | -3.1 ± 21.1 |
| Change at FU Month 24: Appetite Loss | -3.2 ± 20.6 | -3.3 ± 21.0 |
| Change at FU Month 36: Appetite Loss | -3.0 ± 20.4 | -2.7 ± 21.2 |
| Baseline: Insomnia | 25.3 ± 27.4 | 27.3 ± 28.5 |
| Change at Week 13: Insomnia | 6.3 ± 30.3 | 5.1 ± 32.2 |
| Change at Week 25: Insomnia | 4.3 ± 30.6 | 2.0 ± 31.8 |
| Change at EOT: Insomnia | 3.2 ± 31.0 | 0.9 ± 32.8 |
| Change at FU Month 18: Insomnia | -0.1 ± 31.1 | 0.4 ± 32.4 |
| Change at FU Month 24: Insomnia | -1.5 ± 31.3 | -1.1 ± 32.9 |
| Change at FU Month 36: Insomnia | -0.3 ± 31.1 | -0.5 ± 33.5 |
| Baseline: N/V | 2.7 ± 8.2 | 3.1 ± 9.4 |
| Change at Week 13: N/V | 5.6 ± 15.7 | 3.7 ± 14.5 |
| Change at Week 25: N/V | 1.1 ± 11.8 | 0.5 ± 12.4 |
| Change at EOT: N/V | 1.6 ± 12.7 | 0.8 ± 13.2 |
| Change at FU Month 18: N/V | -0.2 ± 10.5 | -0.4 ± 12.1 |
| Change at FU Month 24: N/V | 0.0 ± 10.7 | -0.1 ± 11.8 |
| Change at FU Month 36: N/V | 0.3 ± 11.0 | 0.2 ± 11.7 |
| Baseline: Constipation | 8.7 ± 19.1 | 10.0 ± 19.8 |
| Change at Week 13: Constipation | 1.4 ± 23.5 | 4.1 ± 25.6 |
| Change at Week 25: Constipation | -0.7 ± 21.8 | 0.2 ± 22.8 |
| Change at EOT: Constipation | 0.1 ± 22.4 | 0.9 ± 23.3 |
| Change at FU Month 18: Constipation | 3.0 ± 23.3 | 1.5 ± 23.8 |
| Change at FU Month 24: Constipation | 2.1 ± 23.1 | 0.6 ± 22.9 |
| Change at FU Month 36: Constipation | 2.1 ± 22.9 | 1.5 ± 22.7 |
| Baseline: Pain | 18.8 ± 21.4 | 19.6 ± 22.1 |
| Change at Week 13: Pain | 2.3 ± 25.4 | 5.0 ± 26.1 |
| Change at Week 25: Pain | 1.4 ± 24.1 | 1.4 ± 24.9 |
| Change at EOT: Pain | 0.1 ± 24.7 | 0.5 ± 25.8 |
| Change at FU Month 18: Pain | -1.3 ± 23.3 | -0.5 ± 25.8 |
| Change at FU Month 24: Pain | -1.6 ± 24.2 | -2.2 ± 25.6 |
| Change at FU Month 36: Pain | -2.6 ± 24.4 | -2.3 ± 25.0 |
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall QOL in cancer participants. First 28 questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, N/V, constipation, and pain) and a single item (financial difficulties). Last 2 questions represented participant's assessment of overall health and quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 financial difficulties scores were linearly transformed on a scale of 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicated improvement in financial difficulties and positive values indicated worsening of financial difficulties.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline | 20.3 ± 28.7 | 22.1 ± 30.0 |
| Change at Week 13 | 3.1 ± 26.1 | 1.7 ± 27.0 |
| Change at Week 25 | 2.3 ± 26.8 | -0.3 ± 26.9 |
| Change at EOT | -0.2 ± 27.6 | -1.5 ± 27.2 |
| Change at FU Month 18 | -4.1 ± 27.9 | -5.1 ± 27.5 |
| Change at FU Month 24 | -5.2 ± 28.6 | -6.9 ± 29.3 |
| Change at FU Month 36 | -7.1 ± 28.5 | -8.3 ± 28.3 |
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: Body Image | 79.7 ± 23.5 | 78.9 ± 23.7 |
| Change at Week 13: Body Image | -12.9 ± 24.7 | -13.9 ± 25.2 |
| Change at Week 25: Body Image | -7.6 ± 23.8 | -7.3 ± 23.4 |
| Change at EOT: Body Image | -4.9 ± 23.7 | -6.0 ± 24.6 |
| Change at FU Month 18: Body Image | -0.1 ± 23.3 | -1.3 ± 23.3 |
| Change at FU Month 24: Body Image | 0.5 ± 23.6 | 0.1 ± 23.5 |
| Change at FU Month 36: Body Image | 1.7 ± 24.4 | 0.7 ± 24.6 |
| Baseline: Sexual Enjoyment | 54.0 ± 30.8 | 55.0 ± 30.7 |
| Change at Week 13: Sexual Enjoyment | -16.5 ± 28.4 | -13.1 ± 27.2 |
| Change at Week 25: Sexual Enjoyment | -11.9 ± 26.8 | -7.9 ± 26.5 |
| Change at EOT: Sexual Enjoyment | -10.7 ± 27.5 | -8.0 ± 27.7 |
| Change at FU Month 18: Sexual Enjoyment | -4.2 ± 28.5 | -6.7 ± 26.5 |
| Change at FU Month 24: Sexual Enjoyment | -6.0 ± 28.4 | -5.0 ± 27.6 |
| Change at FU Month 36: Sexual Enjoyment | -5.3 ± 28.1 | -6.0 ± 26.8 |
| Baseline: Sexual Function | 19.6 ± 23.8 | 20.8 ± 24.3 |
| Change at Week 13: Sexual Function | -5.6 ± 20.5 | -6.6 ± 20.7 |
| Change at Week 25: Sexual Function | -2.6 ± 20.8 | -2.3 ± 20.9 |
| Change at EOT: Sexual Function | -1.0 ± 20.8 | -1.4 ± 21.2 |
| Change at FU Month 18: Sexual Function | 2.5 ± 22.8 | 1.4 ± 21.7 |
| Change at FU Month 24: Sexual Function | 2.8 ± 22.9 | 1.8 ± 22.7 |
| Change at FU Month 36: Sexual Function | 2.6 ± 24.0 | 1.6 ± 23.6 |
| Baseline: FP | 51.3 ± 31.7 | 50.5 ± 31.5 |
| Change at Week 13: FP | 3.1 ± 30.2 | 1.8 ± 31.9 |
| Change at Week 25: FP | 6.3 ± 31.1 | 5.4 ± 31.2 |
| Change at EOT: FP | 7.7 ± 32.2 | 6.9 ± 31.8 |
| Change at FU Month 18: FP | 12.9 ± 32.0 | 10.5 ± 32.0 |
| Change at FU Month 24 : FP | 13.7 ± 32.9 | 12.9 ± 32.9 |
| Change at FU Month 36: FP | 14.7 ± 34.1 | 13.6 ± 32.9 |
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.
| units on a scale | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline:Systemic SE | 9.5 ± 10.9 | 10.2 ± 11.2 |
| Change at Week 13: Systemic SE | 21.1 ± 17.5 | 21.7 ± 17.9 |
| Change at Week 25: Systemic SE | 9.2 ± 14.2 | 8.2 ± 14.2 |
| Change at EOT: Systemic SE | 8.3 ± 15.4 | 7.5 ± 14.8 |
| Change at FU Month 18: Systemic SE | 4.4 ± 12.8 | 5.5 ± 13.4 |
| Change at FU Month 24: Systemic SE | 4.1 ± 13.2 | 4.9 ± 13.7 |
| Change at FU Month 36: Systemic SE | 4.5 ± 13.6 | 5.2 ± 13.8 |
| Baseline: Hair Loss | 26.4 ± 32.8 | 22.1 ± 29.0 |
| Change at Week 13: Hair Loss | 17.3 ± 43.6 | 21.2 ± 37.8 |
| Change at Week 25: Hair Loss | 8.3 ± 38.0 | 14.5 ± 38.4 |
| Change at EOT: Hair Loss | 10.9 ± 40.1 | 17.9 ± 39.8 |
| Change at FU Month 18: Hair Loss | -7.0 ± 36.0 | 3.2 ± 34.9 |
| Change at FU Month 24: Hair Loss | -4.1 ± 39.3 | 0.7 ± 36.0 |
| Change at FU Month 36: Hair Loss | -5.6 ± 42.3 | 2.4 ± 34.7 |
| Baseline: Arm Symptoms | 21.6 ± 19.1 | 21.7 ± 19.2 |
| Change at Week 13: Arm Symptoms | -4.7 ± 20.8 | -2.1 ± 21.5 |
| Change at Week 25: Arm Symptoms | -2.9 ± 21.3 | -2.3 ± 21.7 |
| Change at EOT: Arm Symptoms | -3.5 ± 21.5 | -3.4 ± 21.4 |
| Change at FU Month 18: Arm Symptoms | -4.0 ± 21.8 | -3.9 ± 22.5 |
| Change at FU Month 24: Arm Symptoms | -5.1 ± 21.6 | -5.0 ± 22.3 |
| Change at FU Month 36: Arm Symptoms | -5.9 ± 21.8 | -4.7 ± 22.4 |
| Baseline: Breast Symptoms | 19.5 ± 17.5 | 20.4 ± 17.7 |
| Change at Week 13: Breast Symptoms | -5.0 ± 18.4 | -5.2 ± 18.0 |
| Change at Week 25: Breast Symptoms | 1.9 ± 20.7 | -0.4 ± 20.6 |
| Change at EOT: Breast Symptoms | -0.6 ± 20.2 | -3.8 ± 19.7 |
| Change at FU Month 18: Breast Symptoms | -3.0 ± 18.7 | -5.9 ± 18.8 |
| Change at FU Month 24: Breast Symptoms | -6.4 ± 18.4 | -7.3 ± 18.7 |
| Change at FU Month 36: Breast Symptoms | -7.3 ± 18.8 | -7.9 ± 19.0 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in mobility domain was reported: I have no problems in walking about; I have some problems in walking about; and I am confined to bed. Response percentages may not add up to 100% due to data rounding.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: No problems | 93.8 | 92.9 |
| Baseline: Some problems | 6.2 | 6.9 |
| Baseline: Confined to bed | 0.0 | 0.2 |
| Week 13: No problems | 77.5 | 74.8 |
| Week 13: Some problems | 22.1 | 24.8 |
| Week 13: Confined to bed | 0.4 | 0.4 |
| Week 25: No problems | 83.8 | 82.7 |
| Week 25: Some problems | 16.1 | 17.2 |
| Week 25: Confined to bed | 0.1 | 0.1 |
| EOT: No problems | 85.1 | 84.9 |
| EOT: Some problems | 14.8 | 14.9 |
| EOT: Confined to bed | 0.1 | 0.2 |
| FU Month 18: No problems | 88.8 | 87.0 |
| FU Month 18: Some problems | 11.2 | 12.8 |
| FU Month 18: Confined to bed | 0.1 | 0.2 |
| FU Month 24: No problems | 87.8 | 87.7 |
| FU Month 24: Some problems | 12.1 | 12.1 |
| FU Month 24: Confined to bed | 0.1 | 0.1 |
| FU Month 36: No problems | 88.5 | 87.8 |
| FU Month 36: Some problems | 11.5 | 12.1 |
| FU Month 36: Confined to bed | 0.0 | 0.1 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in self-care domain was reported: I have no problems with self-care; I have some problems washing or dressing myself; and I am unable to wash or dress myself. Response percentages may not add up to 100% due to data rounding.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: No problems | 89.7 | 90.7 |
| Baseline: Some problems | 10.0 | 9.1 |
| Baseline: Unable | 0.3 | 0.2 |
| Week 13: No problems | 94.3 | 93.2 |
| Week 13: Some problems | 5.3 | 6.4 |
| Week 13: Unable | 0.4 | 0.4 |
| Week 25: No problems | 95.5 | 95.0 |
| Week 25: Some problems | 4.3 | 4.7 |
| Week 25: Unable | 0.1 | 0.3 |
| EOT: No problems | 95.4 | 95.8 |
| EOT: Some problems | 4.4 | 4.0 |
| EOT: Unable | 0.2 | 0.2 |
| FU Month 18: No problems | 97.2 | 96.0 |
| FU Month 18: Some problems | 2.6 | 3.6 |
| FU Month 18: Unable | 0.2 | 0.3 |
| FU Month 24: No problems | 96.9 | 96.3 |
| FU Month 24: Some problems | 2.8 | 3.5 |
| FU Month 24: Unable | 0.3 | 0.3 |
| FU Month 36: No problems | 97.3 | 96.5 |
| FU Month 36: Some problems | 2.5 | 3.2 |
| FU Month 36: Unable | 0.2 | 0.3 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in usual activities domain was reported: I have no problems with performing my usual activities; I have some problems with performing my usual activities; and I am unable to perform my usual activities. Response percentages may not add up to 100% due to data rounding.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: No problems | 67.4 | 66.1 |
| Baseline: Some problems | 30.4 | 32.2 |
| Baseline: Unable | 2.2 | 1.7 |
| Week 13: No problems | 56.8 | 54.1 |
| Week 13: Some problems | 40.1 | 43.0 |
| Week 13: Unable | 3.1 | 2.9 |
| Week 25: No problems | 66.5 | 65.8 |
| Week 25: Some problems | 32.2 | 32.7 |
| Week 25: Unable | 1.2 | 1.4 |
| EOT: No problems | 72.4 | 72.5 |
| EOT: Some problems | 26.3 | 26.6 |
| EOT: Unable | 1.3 | 0.9 |
| FU Month 18: No problems | 78.5 | 76.3 |
| FU Month 18: Some problems | 20.6 | 23.0 |
| FU Month 18: Unable | 0.9 | 0.7 |
| FU Month 24: No problems | 78.7 | 79.1 |
| FU Month 24: Some problems | 20.4 | 19.7 |
| FU Month 24: Unable | 0.9 | 1.1 |
| FU Month 36: No problems | 80.9 | 79.8 |
| FU Month 36: Some problems | 18.3 | 19.4 |
| FU Month 36: Unable | 0.7 | 0.8 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in pain/discomfort domain was reported: I have no pain or discomfort; I have moderate pain or discomfort; and I have extreme pain or discomfort. Response percentages may not add up to 100% due to data rounding.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: No pain/discomfort | 49.0 | 49.0 |
| Baseline: Moderate pain/discomfort | 50.0 | 49.7 |
| Baseline: Extreme pain/discomfort | 1.0 | 1.3 |
| Week 13: No pain/discomfort | 44.6 | 40.5 |
| Week 13: Moderate pain/discomfort | 52.7 | 56.5 |
| Week 13: Extreme pain/discomfort | 2.7 | 3.0 |
| Week 25: No pain/discomfort | 44.3 | 43.7 |
| Week 25: Moderate pain/discomfort | 53.3 | 54.4 |
| Week 25: Extreme pain/discomfort | 2.4 | 1.9 |
| EOT: No pain/discomfort | 49.3 | 50.0 |
| EOT: Moderate pain/discomfort | 48.5 | 47.6 |
| EOT: Extreme pain/discomfort | 2.2 | 2.4 |
| FU Month 18: No pain/discomfort | 51.3 | 53.1 |
| FU Month 18: Moderate pain/discomfort | 46.6 | 44.7 |
| FU Month 18: Extreme pain/discomfort | 2.1 | 2.1 |
| FU Month 24: No pain/discomfort | 56.7 | 56.0 |
| FU Month 24: Moderate pain/discomfort | 41.3 | 41.5 |
| FU Month 24: Extreme pain/discomfort | 1.9 | 2.5 |
| FU Month 36: No pain/discomfort | 59.5 | 57.8 |
| FU Month 36: Moderate pain/discomfort | 38.9 | 40.1 |
| FU Month 36: Extreme pain/discomfort | 1.6 | 2.1 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions/domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems \[scored as 1\], some or moderate problems \[scored as 2\], and extreme problems \[scored as 3\]). Percentage of participants with each of the following responses in anxiety/depression domain was reported: I am not anxious or depressed; I am moderately anxious or depressed; and I am extremely anxious or depressed. Response percentages may not add up to 100% due to data rounding.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Baseline: Not anxious/depress | 47.1 | 44.7 |
| Baseline: Moderate anxious/depress | 49.4 | 50.1 |
| Baseline: Extreme anxious/depress | 3.5 | 5.2 |
| Week 13: Not anxious/depress | 53.6 | 52.4 |
| Week 13: Moderate anxious/depress | 43.4 | 44.0 |
| Week 13: Extreme anxious/depress | 3.0 | 3.7 |
| Week 25: No anxious/depress | 55.5 | 55.5 |
| Week 25: Moderate anxious/depress | 41.9 | 41.8 |
| Week 25: Extreme anxious/depress | 2.5 | 2.7 |
| EOT: Not anxious/depress | 58.5 | 58.3 |
| EOT: Moderate anxious/depress | 38.9 | 39.1 |
| EOT: Extreme anxious/depress | 2.6 | 2.6 |
| FU Month 18: Not anxious/depress | 61.4 | 59.9 |
| FU Month 18: Moderate anxious/depress | 36.2 | 37.0 |
| FU Month 18: Extreme anxious/depress | 2.4 | 3.1 |
| FU Month 24: Not anxious/depress | 63.8 | 61.0 |
| FU Month 24: Moderate anxious/depress | 33.8 | 36.2 |
| FU Month 24: Extreme anxious/depress | 2.4 | 2.8 |
| FU Month 36: Not anxious/depress | 64.0 | 61.6 |
| FU Month 36: Moderate anxious/depress | 33.3 | 35.4 |
| FU Month 36: Extreme anxious/depress | 2.6 | 3.0 |
| micrograms per milliliter (mcg/mL) | Pertuzumab + Trastuzumab + Chemotherapy |
|---|---|
| Cycle 1 | 68.0 ± 16.6 |
| Cycle 10 | 88.1 ± 34.4 |
| Cycle 15 | 95.5 ± 51.5 |
| mcg/mL | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Cycle 1 | 32.1 ± 13.4 | 34.1 ± 11.4 |
| Cycle 10 | 65.0 ± 39.6 | 68.4 ± 23.0 |
| Cycle 15 | 72.9 ± 46.1 | 71.0 ± 30.4 |
| mcg/mL | Pertuzumab + Trastuzumab + Chemotherapy |
|---|---|
| Cycle 1 | 237 ± 118 |
| Cycle 10 | 222 ± 92.2 |
| Cycle 15 | 206 ± 94.9 |
| mcg/mL | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Cycle 1 | 180 ± 81.0 | 190 ± 51.6 |
| Cycle 10 | 219 ± 94.6 | 225 ± 70.7 |
| Cycle 15 | 187 ± 95.1 | 234 ± 73.5 |
Percentage of participants with IDFS events (excluding SPNBC) is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (that is \[i.e.\], an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ \[DCIS\] and lobular carcinoma in situ \[LCIS\]) and non-melanoma skin cancer were excluded as an event.
| percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 7.1 | 8.7 |
Kaplan-Meier estimate of the percentage of participants who were IDFS event-free (excluding SPNBC) at 3 years is reported. IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event.
| Estimate of percentage of participants | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| Kaplan-Meier Estimate of the Percentage of Participants Who Were IDFS Event-Free (Excluding SPNBC) at 3 Years, as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings | 94.06 (93.09 to 95.03) | 93.24 (92.21 to 94.26) |
Collected over From randomization (for all-cause mortality) or first study treatment (for adverse events [AEs]) until the end of follow-up (up to 12.9 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab + Trastuzumab + Chemotherapy | 205/2,400 (8.5%) | 792/2,364 (33.5%) | 2,353/2,364 (99.5%) |
| Placebo + Trastuzumab + Chemotherapy | 247/2,404 (10.3%) | 686/2,405 (28.5%) | 2,374/2,405 (98.7%) |
| Event | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 211/2364 | 196/2405 |
| DIARRHOEAGastrointestinal disorders | 58/2364 | 18/2405 |
| PYREXIAGeneral disorders | 40/2364 | 46/2405 |
| CARDIAC FAILURECardiac disorders | 44/2364 | 28/2405 |
| NEUTROPENIABlood and lymphatic system disorders | 25/2364 | 34/2405 |
| PNEUMONIAInfections and infestations | 19/2364 | 27/2405 |
| VOMITINGGastrointestinal disorders | 19/2364 | 15/2405 |
| DEHYDRATIONMetabolism and nutrition disorders | 19/2364 | 5/2405 |
| NAUSEAGastrointestinal disorders | 18/2364 | 14/2405 |
| CELLULITISInfections and infestations | 15/2364 | 13/2405 |
| Event | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy |
|---|---|---|
| DIARRHOEAGastrointestinal disorders | 1667/2364 | 1091/2405 |
| NAUSEAGastrointestinal disorders | 1639/2364 | 1582/2405 |
| ALOPECIASkin and subcutaneous tissue disorders | 1594/2364 | 1635/2405 |
| FATIGUEGeneral disorders | 1160/2364 | 1074/2405 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 765/2364 | 867/2405 |
| VOMITINGGastrointestinal disorders | 771/2364 | 727/2405 |
| CONSTIPATIONGastrointestinal disorders | 692/2364 | 762/2405 |
| MYALGIAMusculoskeletal and connective tissue disorders | 620/2364 | 716/2405 |
| ANAEMIABlood and lymphatic system disorders | 667/2364 | 567/2405 |
| STOMATITISGastrointestinal disorders | 666/2364 | 574/2405 |
Intent-to-treat (ITT) population included all randomized participants regardless of treatment received.
| Age, Continuous(years) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Mean | 51.7 ± 10.9 | 51.4 ± 10.7 | 51.5 ± 10.8 |
| Sex: Female, Male(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Female | 2397 | 2396 | 4793 |
| Male | 3 | 8 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 45 | 42 | 87 |
| Not Hispanic or Latino | 432 | 386 | 818 |
| Unknown or Not Reported | 1923 | 1976 | 3899 |
| Race/Ethnicity, Customized(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| White | 1705 | 1694 | 3399 |
| Black | 32 | 41 | 73 |
| Asian | 590 | 598 | 1188 |
| Other | 66 | 69 | 135 |
| Not reported | 7 | 2 | 9 |
| Nodal Status(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| 0 Positive Nodes and Tumor ≤1 cm | 90 | 84 | 174 |
| 0 Positive Nodes and Tumor >1 cm | 807 | 818 | 1625 |
| 1 to 3 Positive Nodes | 907 | 900 | 1807 |
| ≥4 Positive Nodes | 596 | 602 | 1198 |
| Adjuvant Chemotherapy Regimen(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Anthracycline containing regimen | 1865 | 1877 | 3742 |
| Non-anthracycline containing regimen | 535 | 527 | 1062 |
| Hormone Receptor Status(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Negative (ER and PgR negative) | 864 | 858 | 1722 |
| Positive (ER and/or PgR positive) | 1536 | 1546 | 3082 |
| Protocol Version at Enrollment(Participants) | Pertuzumab + Trastuzumab + Chemotherapy | Placebo + Trastuzumab + Chemotherapy | Total |
|---|---|---|---|
| Protocol Version A | 1828 | 1827 | 3655 |
| Protocol Version B | 572 | 577 | 1149 |
Showing the first 100 of 546 sites across 42 countries. Choose a country and city above to see the rest.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Nov 2011 to primary completion in Dec 2016, 61 months.
Results were first posted in Jan 2018, 1 year after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 61 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab